Orchestra BioMed granted stock options to nine new employees, totaling 120,000 shares, under its 2025 New Hire Inducement Plan.
Quiver AI Summary
Orchestra BioMed Holdings, Inc. announced that its Compensation Committee granted stock options for 120,000 shares to nine new employees as part of the company's 2025 New Hire Inducement Plan, in accordance with Nasdaq regulations. The stock options will vest over four years. Orchestra BioMed focuses on developing innovative biomedical technologies through partnerships with leading medical device companies, with significant products in clinical trials, including AVIM Therapy for hypertension and the Virtue® Sirolimus AngioInfusion™ Balloon for atherosclerotic artery disease. Both products have received FDA Breakthrough Device Designation, highlighting their potential in addressing major health issues. For more information, visit their website or follow them on LinkedIn.
Potential Positives
- Orchestra BioMed granted stock options to nine newly hired employees, demonstrating the company's commitment to growing its workforce and attracting talent.
- The stock options are part of the 2025 New Hire Inducement Plan, indicating a structured approach to incentivizing and retaining new employees.
- The company is pursuing pivotal clinical trials for its flagship products, which represent multi-billion-dollar market opportunities, highlighting its potential for significant revenue growth.
- Orchestra BioMed's AVIM Therapy and Virtue SAB both received FDA Breakthrough Device Designation, accelerating their development and commercialization timelines, which could enhance the company's market position.
Potential Negatives
- Granting stock options to nine new employees may raise concerns about the company's reliance on new hires for growth and innovation, potentially indicating staffing or expertise challenges.
- The press release lacks details on the financial implications of the stock option grants, providing no insight into how this may affect shareholder value or company resources.
- While the company highlights promising product candidates, emphasizing ongoing clinical trials without mentioning any potential setbacks or delays may create an impression of withholding critical information from investors.
FAQ
What recent stock option grants did Orchestra BioMed announce?
Orchestra BioMed announced the grant of stock options to purchase 120,000 shares to nine newly hired employees.
Why were stock options granted to new employees?
The stock options were granted as an inducement material under the 2025 New Hire Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).
How long will the stock options vest for new hires?
The stock options granted to new employees will vest over a period of four years.
What is Orchestra BioMed's primary focus?
Orchestra BioMed focuses on biomedical innovation, accelerating high-impact technologies through partnerships with global medical device companies.
What are Orchestra BioMed's flagship products?
The flagship products are Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon, both in pivotal clinical trials.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OBIO Insider Trading Activity
$OBIO insiders have traded $OBIO stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $OBIO stock by insiders over the last 6 months:
- DAVID P HOCHMAN (See Remarks) has made 2 purchases buying 11,000 shares for an estimated $35,290 and 0 sales.
- ERIC S FAIN purchased 5,760 shares for an estimated $15,033
- DARREN SHERMAN (See Remarks) purchased 3,000 shares for an estimated $7,860
- ANDREW LAWRENCE TAYLOR (Chief Financial Officer) purchased 2,000 shares for an estimated $5,100
- JASON ARYEH purchased 1,000 shares for an estimated $2,450
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OBIO Hedge Fund Activity
We have seen 34 institutional investors add shares of $OBIO stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PATHSTONE HOLDINGS, LLC removed 1,006,018 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,174,974
- AFFINITY ASSET ADVISORS, LLC added 727,272 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,803,634
- PERCEPTIVE ADVISORS LLC added 700,000 shares (+15.2%) to their portfolio in Q3 2025, for an estimated $1,736,000
- ALYESKA INVESTMENT GROUP, L.P. removed 365,482 shares (-26.8%) from their portfolio in Q4 2025, for an estimated $1,516,750
- DAFNA CAPITAL MANAGEMENT LLC added 363,636 shares (+inf%) to their portfolio in Q3 2025, for an estimated $901,817
- RENAISSANCE TECHNOLOGIES LLC removed 229,208 shares (-60.2%) from their portfolio in Q4 2025, for an estimated $951,213
- AMH EQUITY LTD added 166,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $411,680
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OBIO Analyst Ratings
Wall Street analysts have issued reports on $OBIO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 12/10/2025
- Chardan Capital issued a "Buy" rating on 11/13/2025
- Barclays issued a "Overweight" rating on 11/12/2025
To track analyst ratings and price targets for $OBIO, check out Quiver Quantitative's $OBIO forecast page.
$OBIO Price Targets
Multiple analysts have issued price targets for $OBIO recently. We have seen 4 analysts offer price targets for $OBIO in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $12.0 on 01/09/2026
- Joshua Jennings from TD Cowen set a target price of $15.0 on 12/10/2025
- Keay Nakae from Chardan Capital set a target price of $20.0 on 11/13/2025
- Yi Chen from HC Wainwright & Co. set a target price of $10.0 on 09/04/2025
Full Release
NEW HOPE, Pa., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on February 12, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 120,000 shares of the Company’s common stock to nine newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options granted to each new employee will vest over a four-year period.
Orchestra Biomed is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue
®
Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit
www.orchestrabiomed.com
, and follow us on
LinkedIn
.
Investor Contact:
Silas Newcomb
Orchestra BioMed
[email protected]
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
[email protected]
